Equids and primates are the only species known to express the placental hormone chorionic gonadotropin (CG). CG is a member of the heterodimeric glycoprotein family and is composed of an ␣ subunit linked to a hormone-specific ␤ subunit. Previously, we have reported that epidermal growth factor (EGF) regulates the equine glycoprotein hormone ␣ subunit promoter through a protein kinase C (PKC)/mitogen-activated protein kinase ( 
INTRODUCTION
Chorionic gonadotropin (CG), luteinizing hormone, follicle-stimulating hormone, and thyroid-stimulating hormone are members of the heterodimeric glycoprotein family [1] . Each hormone is composed of a common ␣ subunit noncovalently linked to a specific ␤ subunit [2] . CG is expressed by the trophoblast cells of primates and equids during gestation and is necessary to maintain progesterone production from the ovary [3] . Human CG (hCG) secretion is regulated by epidermal growth factor (EGF) [4, 5] , activin [6] , interleukin 6 [7] , interleukin 1 [8] , gonadotropin-releasing hormone [9, 10] , norepinephrine [11] , macrophage colony-stimulating factor [12] , retinoic acid [13] , keratinocyte growth factor [14] , and cAMP stimulators [15] . Signaling factors and pathways that regulate secretion and subunit synthesis of equine CG (eCG) in the placenta are largely unknown.
The ␣ subunit, encoded by a single copy gene, is expressed in pituitary of all mammals and in placenta of equids and primates [1, 16] . The ␤ subunit of primate CG is encoded by six genes [16] , whereas the equine CG is encoded by a single copy gene [17] . The proximal 5Ј-flanking region (200 base pairs [bp] ) of the equine and primate/ human ␣ subunit promoter contains a placenta-specific enhancer (PSE) that can be subdivided into two distinct regions: an upstream-regulatory element (URE) and a cAMP responsive region containing two cAMP response elements (CRE) [18] [19] [20] [21] [22] [23] (Fig. 1) . The URE region can be further subdivided into a trophoblast-specific element (TSE) and an ␣-activating element (␣-ACT). In humans, the first 180 bp of the ␣ subunit promoter is sufficient for trophoblast expression. The nucleotide sequence within the proximal 5Ј-flanking region of the ␣ subunit promoter is highly conserved between humans and equids. However, the equine TSE contains a single base pair change that disrupts binding of the TSE-binding protein [24] . In addition, the equine ␣ subunit promoter harbors a single copy of a variant form (TGAtGTCA) of the CRE [21, 25] . The variant CRE has significantly reduced affinity for CRE-binding protein (CREB) and preferentially binds CRE modulator (CREM), activator transcription factor 2 (ATF-2) and c-jun transcription factors [26] . In contrast with humans, we have shown that the major regulatory element responsible for basal expression of the equine ␣ promoter resides between Ϫ2800 and Ϫ2300 [27] . Additional element(s) located between Ϫ2300 and Ϫ1900 appear to assist in basal expression in the JEG-3 human choriocarcinoma cell line [27] .
Recently, two different laboratories have shown that EGF regulation of the human ␣ subunit promoter is mediated through its CRE elements [28, 29] . Matsumoto and coworkers reported that EGF regulation of the human ␣ subunit promoter occurred via phosphorylation of CREB and binding to the CRE element in the Rcho-1 rat placental cell line [28] . In contrast, Roberson and coworkers have shown that EGF alone has only a minimal effect on stimulation of human ␣ subunit promoter (Ϫ845/ϩ49) but can synergize with forskolin. Treatment with EGF plus forskolin resulted in the recruitment of a heterodimer of c-fos and c-jun (members of the activator protein 1 [AP-1] family) to the CRE [29] . Under basal conditions, this element has been shown to interact with CREB, CREM, activator transcription factor (ATF-1 and ATF-2), and c-jun [26] . Furthermore, regulation of human ␣ subunit by EGF required activation of both the extracellular-signal regulated kinase (ERK) and Jun N terminal kinase (JNK) mitogen activated protein kinase pathways (MAPK). Although EGF activates the p38 MAPK signal transduction pathway, it was not in-
The schematic presentation of 5Ј flanking region of the human and equine ␣ subunit promoter and transcription factors that interact with these elements. PSE, Placenta-specific enhancer; URE, upstream regulatory element; CRE, cAMP response elements; TSE, trophoblast specific element; ␣ ACT, alpha-activating element; JRE, junctional response element; DRE, downstream response element; CCAAT, a canonical CAAT box; AP-2, activator protein 2; GCMa, glial cell missing 1; GATAs, GATA zinc finger binding transcription factor; bZIP transcription factors (CREB, CREM, ATF, c-jun); ␣CBF, ␣ subunit CCAAT-binding factor.
volved in EGF induction of the human ␣ promoter in the JEG-3 cells [29] .
It is evident that EGF also plays an important role during equine implantation (Days 30-34). Prior to Day 38 of gestation, low levels of EGF are present in the endometrium [30] . Expression of EGF was markedly upregulated in the epithelium of endometrial glands from Day 38 onward, which coincides with the period of placentation [30] . In addition, EGF binding was observed in equine allantochorion from Day 30 to Day 34 (implantation) as well as in the fully developed placenta at Days 150-250 [30] . Previously, we have shown that both EGF and phorbol 12-myristate 13-acetate (PMA), a classical PKC activator, induce activity of the e␣(Ϫ2800/ϩ21) promoter in JEG-3 cells [27] . Regulation of equine ␣ promoter by EGF/PMA was mediated by the ERK signal transduction pathway. The region of the promoter between Ϫ2300 and Ϫ1900 bp was determined to be responsible for this induction. In addition, we have reported that both activators of cAMP dependent protein kinase A and protein kinase C induce the steady state mRNA level of equine ␣ subunit in equine trophoblast cell lines [31] . Unfortunately, we have been unable to use these cell lines to study regulation of the equine ␣ subunit promoter due to the fact that these cell lines are refractory to common transfection methods. In the current study, we have used the JEG-3 human choriocarcinoma cell line to identify the regulatory element and factors that mediate EGF induction of the equine ␣ subunit promoter.
MATERIALS AND METHODS
Human recombinant EGF (cat. #E9644) and PMA were purchased from the Sigma Chemical Co. Cell Culture, Transient Transfections, and Reporter Assays Immortalized equine girdle cell line (eCG500.1) was cultured in Dulbecco modified Eagle medium (DMEM) containing 10% fetal bovine serum (FBS), 5% horse serum, and antibiotics at 37ЊC and 5% CO 2 in 100-mm tissue-culture plates. The JEG-3 choriocarcinoma cell line was cultured and transfected as previously described [27] . Briefly, cells were plated a day before transfection at a density of 1.1 ϫ 10 5 cells per well in 6-well plates. The next day, the cells were transfected with 1.0 g of reporter plasmid, 200 ng of RSV ␤-galactosidase (as an internal control for transfection efficiency), and 5 l of LipofectAmine (Life Technologies Inc.) according to the manufacturer's recommendations. The following morning, the transfection media was replaced with normal growth media (DMEM with 10% FBS and antibiotics). The cells were serum starved the following evening. The EGF (100 ng/ml) or PMA (10 nM) treatment (serum-free media) was administered the next morning and cultured for 8 h or overnight, respectively, in serum-free media. The cells were harvested and assayed as previously described [27] . The luciferase value for each sample was divided by its corresponding ␤-galactosidase level to give an adjusted luciferase.
RNA isolation and analysis. ECG 500.1 cells were cultured in 100-mm plates until they reached 80%-85% confluency as stated above and were treated with various concentrations of human recombinant EGF (50, 100, and 200 ng/ml) for 20 h. Total RNA was isolated using Trizol Reagent (Life Technologies). Total RNA (10-15 g) was separated by electrophoresis through a 1.0% formaldehyde-agarose gel and Northern analysis was performed according to the protocol described previously [31] . An equine ␣ cDNA was used to synthesize random primer-generated 32 P-labeled cDNA probes. Following autoradiography, the blots were stripped and rehybridized with a radiolabeled cDNA probe for equine ribosomal protein L7 as an internal control. Specific signals were quantitated using a PhosphorImager (Molecular Dynamics, Sunnyvale, CA), and these values were adjusted by taking the ratio of specific signals (such as e␣) to that of the control L7.
Plasmid Constructs
The pGL3 basic reporter plasmid was used as a vector to make all promoter constructs. The promoter constructs for e␣Ϫ2800/ϩ21, Ϫ2300/ ϩ21, and Ϫ1900/ϩ21 were previously reported [27] . The e␣Ϫ2110, Ϫ2045, and Ϫ2020 constructs were generated by PCR. The following strategy was used to generate the e␣(Ϫ2045/ϩ21) A construct. A sense oligodeoxynucleotide encompassing bases Ϫ2045 to Ϫ2015 with a mutation in the A element (Ϫ2039/Ϫ2032) and an antisense oligodeoxynucleotide encompassing bases ϩ21 to ϩ5 were used for PCR. The upstream oligodeoxynucleotide mutated the A element from TGAATCA to gtcgaCA, generating a SalI site. The PCR product was kinased, digested with NdeI, and subsequently subcloned into a SmaI/NdeI-digested wild type promoter construct. A different strategy was used to generate the e␣ (Ϫ2045/ϩ21) B construct. An antisense oligodeoxynucleotide encompassing bases Ϫ2022 to Ϫ2053 and an upstream oligodeoxynucleotide (RV3, located upstream of multiple cloning site of the pGL3 vector) were used in a first PCR reaction while a sense oligodeoxynucleotide (Ϫ2045 to Ϫ2015) and an antisense oligodeoxynucleotide (ϩ21 to ϩ5) were used in a second PCR reaction. The PCR fragments mutated the B element (Ϫ2012/Ϫ2005) from GCGTCAGT to agcTCgag, generating an XhoI site. These two PCR products were used as template in a third PCR reaction using the RV3 and an antisense oligodeoxynucleotide (ϩ21 to ϩ5) primers to generate the full PCR product. This PCR product was digested with MluI/NdeI and subsequently subcloned into the MluI/NdeI sites of the wild-type promoter. All constructs generated by the PCR method were sequenced to confirm that the appropriate mutation had been made and to ensure that a random point mutation had not been made in the native sequence. The Raf BXB and ␦Raf expression constructs were provided by Dr. Ulf Rapp (Universitat Wurzburg, Germany) and Dr. Dennis Templeton (Case Western Reserve University), respectively, and have been reported previously [27] . The 7X-AP1 construct has been described previously [27] .
FIG. 2. PMA/ERK responsiveness of 5Ј deletion constructs in JEG-3 cells. A)
Cells were transiently transfected according to the procedures outlined in the Materials and Methods and treated with 100 ng/ml EGF for 8 h. Cell lysates were harvested and measured for luciferase activity. Luciferase activity was adjusted to that of the ␤-galactosidase activity. Data is presented as fold induction Ϯ SEM above basal levels. B) Regulation of the equine ␣ promoter by the ERK pathway. JEG-3 cells were cotransfected with 500 ng of two different constitutively active Raf kinases (␦Raf and Raf BXB) along with 1 g of the various equine ␣ promoters or a 7X-AP1 reporter construct. All Raf constructs transactivated the Ϫ2300, Ϫ2110, and Ϫ2045 equine promoters as well as 7X-AP1. These kinases failed to activate the equine promoters of Ϫ2020 and Ϫ1900. Constructs were evaluated in triplicate and repeated at least three times. * and ** represent P value Ͻ 0.05.
Nuclear Extract Preparation and Electrophoretic Mobility Shift Assays
Cells were cultured until 70-85% confluent in 150-mm plates using conditions described above. Cells were subsequently serum starved for 16-20 h, followed by stimulation with 100 ng/ml EGF (0, 1, 2, and 4 h). Nuclear extracts were prepared according to Daggett and coworkers [32] and stored at Ϫ80Њ C. Oligodeoxynucleotides were end-labeled with 32 P-ATP using T4 polynucleotide kinase, purified through a 6% polyacrylamide gel, and used as electrophoretic mobility shift assay (EMSA) probes. The nuclear extracts (10-20 g) were incubated for 15 min at 4ЊC in the binding reaction buffer (10 mM HEPES pH 7.9, 20 mM KCl, 5 mM MgCl 2 , 10 M ZnCl 2 , 1 mM EDTA, and 10% glycerol) containing 0.15 g of poly(dI-dC) and 0.1 g of salmon sperm DNA in total reaction volume of 20 l. Competitor and radiolabeled probe (25 fmol) were added and incubated for an additional 15 min at room temperature. The DNAprotein complexes were resolved on a 4% nondenaturing polyacrylamide gel (prerun for 15 min at 240 V) run at 4ЊC using 0.5ϫ Tris-borate-EDTA buffer. The gel was transferred to blotting paper (Schleicher & Schuell Inc., Keene, NH), dried, and exposed to x-ray film. Experiments utilizing antibodies were conducted as follows: 1-2 l of antibody was added to the binding reaction and incubated for 30 min at 4ЊC prior to the addition of the probe. The sequences of probes (e␣Ϫ2045, e␣Ϫ2045A, and e␣Ϫ2020) used in EMSA are shown in Figure 3A . Consensus AP-1 (cAP-1) oligo was purchased from Promega Corp. The h␣CRE (palindromic) and TGAT (variant CRE) were described previously [26] . The sequence of the equine ␣CRE used as a competitor was 5Ј-TCAATTGATGTCA-TATAATT-3Ј.
Western Analysis
JEG-3 cells were cultured until 60-70% confluent in 100-mm plates. Cells were serum starved overnight and subsequently treated with 100 ng/ ml human recombinant EGF for 0, 1, 2, and 4 h in serum-free media. Nuclear proteins were isolated according to the method described by Daggett and coworkers [32] . Proteins (100 g) were resolved on a 10% SDS-PAGE gel and transferred to an Immobilin-P membrane (Millipore, Bedford, MA). Equivalent protein loading was determined by staining the blot with Ponceau-S. Subsequently, the membrane was immunoblotted with anti c-fos (sc-052) and JunD (sc-74) and signals were detected using enhanced chemiluminescence.
Statistical Analysis
All transient transfection experiments were performed in triplicate and repeated a minimum of three times. Statistics were performed where noted, using one-way ANOVA followed by Duncan multiple range test. A P value Յ0.05 was considered significant.
RESULTS

Identification of the EGF/PMA Responsive Element
Previously, we reported that regulation of the equine ␣ promoter by EGF is mediated through a PKC pathway and that the critical EGF/PMA responsive region was located between Ϫ2300 and Ϫ1900 bp of the ␣ promoter. We have subsequently examined the role of EGF in regulating the expression of the equine ␣ subunit gene in immortalized equine chorionic girdle cells (eCG 500.1). Treatment with EGF (100 ng/ml) for 20 h induced equine ␣-mRNA expression 2.9 Ϯ 0.5-fold (data not shown). This further strengthens the role of EGF in regulation of equine CG genes.
To identify the EGF/PMA responsive element(s), we generated a series of deletion constructs (e␣Ϫ2110/ϩ21, Ϫ2045/ϩ21, and Ϫ2020/ϩ21) and evaluated them in transient transfection assays (Fig. 2A) . The e␣Ϫ2300/ϩ21 and 7X-AP1 luciferase promoter constructs were included as positive controls while the pGL3 basic and e␣(Ϫ1900/ϩ21) vectors were included as negative controls. The transfected cells were serum starved and treated with either EGF (100 ng/ml) for 8 h or 10 nM PMA overnight. Both the e␣(Ϫ2110/ϩ21) and (Ϫ2045/ϩ21) promoter constructs responded to EGF stimulation (P Ͻ 0.05), while the e␣(Ϫ2020/ϩ21) construct was unresponsive and similar to the e␣(Ϫ1900/ϩ21) promoter construct described previously ( Fig. 2A) . Similar results were obtained with PMA (data not shown). These data suggest that the PMA/EGF responsive element(s) must reside within a 25-bp region (Ϫ2045 to Ϫ2020) of the promoter. The DNA sequence in this distal region of the promoter is distinct from the proximal variant CRE element as well as a palindromic CRE element in the human ␣ promoter. These data suggest that the regulatory mechanism used by EGF to regulate the equine ␣ promoter is quite distinct from that of human ␣ promoter.
Raf Kinases Stimulate the Equine ␣ Promoter
We have previously shown that EGF/PMA regulation of the equine ␣ promoter was mediated through a Raf/ERK signal transduction pathway in JEG-3 cells [27] . The response to EGF involved the activation of the ERK but not 4) and the cAP-1 (lanes 8-10) competed very well, while an oligodeoxynucleotide containing a mutation of the A element (lanes 5-7) failed to compete. Molar Ex, molar excess. Arrows indicate the specific protein-DNA complex.
the JNK and p38 MAPK signaling pathways. To determine whether the region between Ϫ2045 and Ϫ2020 was also regulated by the Raf/ ERK pathway, we cotransfected cells with the e␣-promoter constructs along with two different constitutively active forms of Raf kinase, ␦Raf and Raf-BXB. Raf kinases (c-Raf-1, A Raf, and B-raf) are upstream activators of the MAPK pathway that specifically activate ERK 1 and 2 [33, 34] . Both Raf kinases transactivated the longer e␣ constructs but failed to activate the e␣Ϫ2020/ ϩ21 and Ϫ1900/ϩ21 constructs (Fig. 2B) . The ␦Raf and RafBXB kinases induced the e␣Ϫ2300 promoter (6.65 Ϯ 0.95-and 13.4 Ϯ 0.61-fold, respectively; P Ͻ 0.005), e␣Ϫ2110 (4.8 Ϯ 0.2-and 12.9 Ϯ 0.7-fold, respectively; P Ͻ 0.005), and Ϫ2045 (5.2 Ϯ 0.8-and 7.9 Ϯ 0.78-fold, respectively; P Ͻ 0.005). The ␦Raf and RafBXB kinases induced the control 7X-AP1 promoter 31 Ϯ 4.0-and 45 Ϯ 2.3-fold, respectively. Together with the deletion mutagenesis studies, these data suggest that EGF/ERK regulation of the equine ␣ promoter occurs primarily through this 25-bp region located between Ϫ2045 and Ϫ2020 bp (Fig. 3A) . It is interesting to note that the e␣Ϫ2020/ϩ21 retained two AP-1-like elements (B and C in Fig. 3A ) and yet it was unresponsive to EGF/PMA stimulation or Raf overexpression.
A Heterodimeric Protein Complex Is Involved in Regulation of the Equine ␣ Promoter
To analyze and identify the transcription factor(s) activated by EGF and PMA, we used the 25-bp region spanning Ϫ2045 to Ϫ2020 of equine ␣ promoter as a probe in an EMSA. This 25-bp region harbors an AP-1-like element (Fig. 3A) . Time-dependent induction of protein binding to this DNA sequence was observed following stimulation by EGF (Fig. 3B) . Maximum protein binding to the e␣Ϫ2045/ Ϫ2020 probe was evident using extracts from cells treated with EGF for 4 h (Fig. 3B) . Interestingly, significant protein binding to the cAP-1 probe was observed at 1 h (Fig. 3B) . In order to determine the binding specificity of this protein complex, we performed a series of competition assays. Protein binding to the e␣Ϫ2045/Ϫ2020 was entirely competed off by a 50-fold molar excess of unlabeled wild-type oligodeoxynucleotide, indicating specific binding of this complex to the radiolabeled oligodeoxynucleotide (Fig. 3C) . We also competed with an oligodeoxynucleotide probe in which site A (Fig. 3A) was mutated. This mutant oligodeoxynucleotide failed to compete for protein binding, suggesting that this protein complex interacts specifically with the A site within the Ϫ2045/Ϫ2020 sequence. This element had homology to a consensus AP-1 (cAP-1) site, with only a single base pair change (Fig. 3A) . Addition of a cAP-1 oligodeoxynucletide effectively competed for protein binding (Fig. 3C) , suggesting that the complex may consist of AP-1-like proteins.
To further delineate the protein(s) binding to this site and DNA sequence preferences, we performed competition assays using various response elements from the ␣ subunit gene that have been shown to interact with AP-1 proteins FIG. 4 . Binding specificity of the protein complex to the e␣Ϫ2045A region. EMSAs were performed using radiolabeled e␣2045 probe and nuclear extracts from JEG-3 cells treated with or without EGF for 4 h. The core sequence for the probe/competitors is indicated along the left-hand side of the figure. A 25 (lanes 3, 5, 7, 9 , 11, and 13)-or 250 (lane 4, 6, 8, 10, 12 , and 14)-fold molar excess of unlabeled competitors was used. The sequence for e␣2045 and e␣2020 are described in Figure 3A . H␣CRE (5Ј-GATCAAATTGACGT-CATGGTAAA-3Ј) and TGAT (5Ј-GAT-CAAATTGATGTCA TGGTAAA-3Ј) oligodeoxynucleotides include a palindromic and a variant CRE element from ␣ subunit promoters, respectively. E␣CRE (5Ј-TCAAT TGATGTCATATAATT-3Ј) included a single variant CRE element with different flanking sequences to that of TGAT. Molar Ex, molar excess. Arrows indicate the specific protein-DNA complex. (Fig. 4) . In terms of the AP-1 family of proteins, the h␣CRE interacts with c-jun and c-fos, while h␣TGAT and the e␣CRE preferentially bind to c-jun [26, 29] . We also included the cAP-1 oligo, the e␣ 2045 wild-type probe, and a downstream segment of the e␣ promoter (e␣2020) that contained two AP-1-like elements (B and C in Fig. 3A) . A 25-and 250-fold molar excess of competitor were used to compete the complex. The unlabeled wild-type oligodeoxynucleotide (e␣2045) completely competed at 25-fold molar excess. It is interesting to note that cAP-1, h␣CRE, and e␣2020 competed moderately well while h␣TGAT and e␣CRE competed very weakly. The relative binding affinity of this complex to these sequences appears as e␣2045 Ͼ cAP-1, h␣CRE and e␣2020 Ͼ h␣TGAT and e␣CRE. This suggests that this complex binds more efficiently to the A site of e␣ 2045 sequence than it does to a cAP-1, CRE site or the B and C sites downstream of site A.
The nature of the protein complex was investigated by supershift EMSAs using a series of antibodies that bind AP-1 proteins (Fig. 5A ). Other antibodies (USF-1, USF-2, SP-1, and Ets-1) were included as negative controls. Among these antibodies, c-fos effectively shifted the complex. Approximately 60% of complex was shifted with the c-fos antibody (Fig. 5A) , while c-jun and JunB failed to supershift the complex. In addition, the Jun* antibody, which recognizes all members of the Jun family of transcription factors (cjun, JunB, and JunD, recognizes DNA binding domain of these transcriptions) disrupted protein binding as effectively as did the c-fos antibody. Because this antibody inhibits the binding of the jun proteins to DNA and the cjun and JunB antibodies had no effect, it suggested that JunD was in the complex. Additional EMSAs were performed using antibodies to c-fos and the Jun family members, including JunD (Fig. 5B) . C-fos alone supershifted, while Jun* and JunD depleted the complex, suggesting that this complex is predominantly composed of a c-fos/JunD heterodimer that interacts with element A.
EGF Regulation of c-fos and JunD
We have shown that a heterodimer of c-fos and JunD preferentially interacts with element A in the equine ␣ promoter following stimulation with EGF. Previously, it had been shown that c-fos and c-jun are induced shortly after treatment with EGF in JEG-3 cells [29] . We examined the expression of c-fos and JunD in response to EGF stimulation in JEG-3 cells using Western blot analysis. Consistent with previous reports, c-fos was induced following a 1-h exposure to EGF and was maintained until 4 h (Fig. 6) . In contrast, JunD was induced at 4 h (Fig. 6 ) and was maintained until 8 h (data not shown). These data suggest that EGF differentially induces c-fos and JunD in JEG-3 cells.
Functional Analysis of AP-1 Elements in the Promoter
To determine the functional significance of element A (referred to as eAP-1 element) in EGF/PMA/ERK stimulation of the equine ␣ promoter, we generated a promoter construct that contained a mutation in this element (same mutation as that used in the EMSA studies). Because the B/C elements had some affinity for the c-fos/JunD complex (Fig. 4) , we reasoned that the presence of these sites may play a role in EGF/PMA/ERK stimulation of the promoter in conjunction with the eAP-1 element. Therefore, we created a mutation in the B/C elements in the context of the Ϫ2045 to ϩ21 promoter. These constructs were evaluated for responsiveness to EGF (Fig. 7A ) and Raf kinase (Fig.  7B) . EGF induced activity of the e␣Ϫ2300 (2.1 Ϯ 0.2-fold), e␣Ϫ2045 (2.1 Ϯ 0.26-fold), and e␣Ϫ2045B/C (2.2 Ϯ 0.14-fold) promoters (P Ͻ 0.01), while the e␣Ϫ2020 and e␣Ϫ1900 constructs were unresponsive to EGF. Mutation of the eAP-1 site (e␣Ϫ2045〈) blocked EGF stimulation of the promoter, suggesting that the eAP-1 element has functional significance. The ␦Raf and RafBXB kinases transactivated the e␣-2045 (4.5 Ϯ 0.9-and 5.6 Ϯ 1.0-fold, respectively; P Ͻ 0.001) and e␣Ϫ2045B/C promoters (3.2 Ϯ 0.2-and 4.4 Ϯ 0.7-fold, respectively; P Ͻ 0.005). Mutation of the eAP-1 site severely attenuated Raf activation of the e␣ promoter (2.1 Ϯ 0.3-and 2.6 Ϯ 0.6-fold, respectively), confirming the functional significance of this element (Fig. 7B) . This also supports the loss of responsiveness of the e␣Ϫ2020/ϩ21 promoter to EGF/PKC/ERK stimulation. Mutation of the DNA sequence representing the B/C sites slightly reduced the ability of Raf kinase to activate the promoter. This is not entirely surprising because B/C elements have some affinity for the c-fos/JunD heterodimer (Fig. 7B) . However, this reduction was not evident following stimulation with EGF (Fig. 7A) . 
DISCUSSION
The placenta is a unique organ in that its morphology varies greatly across species. In rodents, it is classified as being invasive and hemochorial. The progenitor cells differentiate into four different lineages (trophoblast giant cells, spongiotrophoblasts, syncytium, and glycogen cells) for proper placental development [35, 36] . The human placenta is invasive, hemochorial, and discoid. Proliferating stem cells are programmed to undergo differentiation into two different lineages, syncytiotrophoblast and invasive trophoblasts, where the former synthesize CG [37] . In horses, the placenta is defined as noninvasive, epitheliochorial, and diffuse. Chorionic girdle cells, specialized trophoblast cells, differentiate to form endometrial cups, which synthesize CG [38, 39] .
Many studies have shown the importance of EGF signaling during implantation and placentation in rodent models. Synchronized expression of the EGF receptors is necessary for successful implantation of embryos in mice [40] . Targeted disruption of the EGF-R gene in mice resulted in trophoblast defects and death at midgestation [41] . In addition, EGF has been shown to play an important role in trophoblast proliferation, invasion, and differentiation [4, [42] [43] [44] . Furthermore, EGF also promotes amino acid transport in the rat placenta, influencing fetal growth [45] , and regulates the transplacental supply of glucose [46] .
In humans, EGF has been shown to block the cytokineinduced apoptosis of human cytotrophoblasts and syncytiotrophoblasts from normal term placentas in vitro [47, 48] . EGF also lowered the apoptotic effect induced by hypoxia in cultured trophoblasts [49] . Furthermore, EGF increases secretion of human CG in differentiating cytotrophoblasts [4, 5] . Cao and coworkers have shown that EGF increased the stability of the hCG␣ and ␤ mRNAs in JEG-3 cells [50] .
The mechanisms involved in regulation of the CG subunit genes by various signal transduction pathways is not clear, especially for equids. The EGF stimulus is a common factor in regulating the ␣ subunit gene of both humans and horses, and perhaps represents the existence of a conserved signaling system for stimulating the CG genes. Our studies have shown that the regulation of the equine ␣ subunit by EGF is mediated through a PKC/Raf/ERK signal transduction cascade in trophoblasts [27] . Activation of this signal transduction cascade induced the binding of a heterodimeric AP-1 complex to a cis-acting eAP-1 element located in an upstream region of the equine ␣ promoter (Ϫ2039 to Ϫ2032). This increased binding activity correlates with an increase in promoter activity. Furthermore, Raf kinase transactivates the equine ␣ subunit promoter through this response element. One member of this heterodimeric complex is c-fos, and it appears to heterodimerize with Jun-D. Heterodimerized cfos/JunD preferentially interacted with this eAP-1 element as compared with a cAP-1 element. It FIG. 7 . Functional analysis of the eAP-1 element (site A) in the equine ␣ subunit promoter. Response of equine e␣ promoters to EGF (A) and Raf kinase (B). A) EGF regulation of truncated wild-type e␣ promoters and mutant constructs. Transfected cells were treated with 100 ng/ml EGF for 8 h, cell lysates were harvested and measured for luciferase activity. Mutation of the eAP-1 (A) element diminished its responsiveness to EGF while mutation of B/C element maintained its responsiveness. This representative data is presented as fold induction Ϯ SEM above basal levels. B) Wild-type and mutant e␣ promoter constructs were cotransfected with pcDNA3, RafBXB, or ␦Raf and evaluated for luciferase activity. Constitutively active Raf transactivated the Ϫ2800 and Ϫ2045 equine promoters as well as the 7X-AP1 construct. However, mutation of the eAP-1 (A) element diminished responsiveness. Mutation of the B/C response element had a minimal effect on transduction of the promoter. Raf failed to activate the Ϫ2020 equine promoter and pGL3 basic. Constructs were evaluated in triplicate and repeated at least three times. *P Ͻ 0.05.
is interesting to note that the h␣CRE has a similar binding affinity to this complex, as does the cAP-1 response element. Interestingly, the B/C element could compete for protein binding to the eAP-1 site, and its relative affinity was similar to that of cAP-1 and h␣CRE. However, in the absence of the Ϫ2045 to Ϫ2020 segment of the promoter, the B/C elements failed to respond to stimulation by EGF, PKC, or Raf overexpression. Although sequences of the eAP-1 and B/C are similar, the B/C elements do not appear to have a central role in the context of the Ϫ2045 promoter.
Our data support previous findings where the human ␣ subunit promoter (1500 bp) failed to respond to EGF alone in JEG-3 cells [29] . Truncation of the equine ␣ subunit promoter (either 2020 or 1900) resulted in a failure to respond to EGF/ERK activation. The current data suggest that EGF regulation of the equine ␣ subunit is distinct from that of the human ␣ subunit gene and opens the possibility that similar elements to those identified in the equine promoter may exist upstream of Ϫ1500 in the human ␣ subunit promoter. Nonetheless, it is evident that members of the AP-1 family of transcription factors play important roles in EGF regulation of the glycoprotein ␣ subunit gene of both equids and humans.
It is very interesting to note that some AP-1 transcription factors such as Fra-1 and JunB have been shown to be essential for placental development in mice. Fetal mice lacking Fra-1 were severely growth retarded and died between E10.0 and E10.5 as the result of a reduced labyrinth layer [51] . Similarly, mice lacking JunB die between E8.5 and E10.0 due to lack of a vascularized labyrinth layer [52] . Although other AP-1 factors such as c-fos have been disrupted, such mice do not show severe placental phenotypes as compared with Fra-1 and JunB. Interestingly, it has been shown that Fra-1 can maintain the functional equivalence of c-fos during vertebrate evolution [53] . However, the Fra-1 knockout data suggest that c-fos cannot functionally replace Fra-1 during placental vascularization. Unlike the aforementioned AP-1 proteins, much less is known about JunD. The JunD gene has been disrupted and is reported to lead to a defect in spermatogenesis, but these mice were viable [54] . Transcriptional activation by JunD has been shown to be blocked by the tumor suppressor protein menin [55] [56] [57] . Its role in placenta is unknown. Furthermore, heterodimerized JunD/Fra2 has been shown to bind AP-1 and CRE elements to trigger gene expression in PC12 cells [58] , and induction of JunD/Fra2 was observed in differentiating granulosa cells [57] . The current study is the first to document a role for JunD in trophoblast function.
The expression profile for some of these immediate early genes during the process of human trophoblast differentiation has been reported. Dakour and coworkers [59] have shown that expression of c-fos and JunB increases in response to EGF stimulation in spontaneously differentiating cytotrophoblast cells. In addition, levels of CREB and ATF-1 have been shown to increase during syncytium formation [60] . However, the role of JunD in the process of trophoblast differentiation remains to be investigated. Nonetheless, numerous AP-1 transcription factors play very important roles during placental development. Their role in equine placental development and function require further investigation.
In summary, the regulation of equine ␣ subunit expression by the EGF/PKC/ERK signal transduction pathway is mediated by a heterodimeric protein complex, which was identified to contain c-fos and JunD. In contrast to studies of the human ␣ subunit promoter and its proximal CREs, this complex interacts with a distally located element in the equine ␣ promoter. This element mediates EGF regulation of the promoter. Furthermore, it appears that similar response elements exist within the human ␣ subunit promoter and the possibility exists that these elements may mediate EGF and PKC regulation in human trophoblasts.
